Full titration schedule, Ozempic vs. Wegovy protocol comparison, missed dose instructions, side effects by dose level, and data from 5 key clinical trials including STEP 1 and SELECT.
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist — a synthetic analogue of the endogenous GLP-1 hormone that is secreted by intestinal L-cells in response to food intake. It shares 94% amino acid sequence homology with native GLP-1 but has been modified with a C-18 fatty acid chain attached via a linker to lysine at position 26, enabling albumin binding and extending the half-life from 2 minutes (native GLP-1) to approximately 7 days — enabling once-weekly dosing.
The primary mechanisms relevant to dosing are: (1) dose-dependent insulin secretion stimulation in the presence of elevated blood glucose, (2) dose-dependent glucagon suppression, (3) delayed gastric emptying which reduces post-meal glucose spikes and contributes to satiety, and (4) central appetite suppression via GLP-1 receptors in the hypothalamus and brainstem. The weight loss effect is primarily driven by mechanisms 3 and 4, which is why higher doses produce greater weight loss.
Why titration matters: The dose-dependent nature of GLP-1 receptor agonism means that higher doses produce greater appetite suppression and weight loss — but also greater gastrointestinal stimulation. The titration schedule exists to allow GI adaptation at each dose level before escalating, minimizing nausea and vomiting while maximizing therapeutic effect.
Semaglutide dose escalation schedule. Wegovy continues to 2.4 mg maintenance; Ozempic typically stops at 0.5–1.0 mg for T2D. For research purposes only.
This schedule applies to both Ozempic (T2D) and Wegovy (obesity), though the target maintenance dose differs. Wegovy continues to 2.4 mg; Ozempic typically stops at 0.5–1.0 mg for T2D management.
| Period | Dose | Frequency | Purpose | Expected Weight Loss | Notes |
|---|---|---|---|---|---|
| Weeks 1–4 | 0.25 mg | Once weekly | Initiation — tolerance establishment | Minimal (~1–2%) | Do not increase early. GI side effects most common here. |
| Weeks 5–8 | 0.5 mg | Once weekly | First therapeutic dose | ~3–5% | Most patients tolerate this dose well. First measurable appetite suppression. |
| Weeks 9–12 | 1.0 mg | Once weekly | Standard maintenance | ~7–10% | FDA-approved maintenance dose for T2D (Ozempic). Significant appetite reduction. |
| Weeks 13–16 | 1.7 mg | Once weekly | Escalation (obesity only) | ~12–14% | Wegovy-specific dose. Not available in Ozempic pen. |
| Week 17+ | 2.4 mg | Once weekly | Maximum approved dose (obesity) | ~15–17% | STEP trial maximum dose. Highest weight loss efficacy. Wegovy 2.4mg pen. |
Both are semaglutide — the same molecule. The difference is the approved indication and target maintenance dose.
| Aspect | Ozempic (T2D) | Wegovy (Obesity) |
|---|---|---|
| Indication | Type 2 Diabetes (T2D) | Chronic weight management (obesity/overweight) |
| Starting dose | 0.25 mg/week × 4 weeks | 0.25 mg/week × 4 weeks |
| Maintenance dose | 0.5–1.0 mg/week | 2.4 mg/week |
| Maximum dose | 2.0 mg/week | 2.4 mg/week |
| Titration period | 4–8 weeks to maintenance | 16–20 weeks to maximum |
| Expected weight loss | ~6–8% (T2D population) | ~15–17% (obesity population) |
| Primary outcome | HbA1c reduction | Body weight reduction |
| Pen device | Ozempic pen (0.25/0.5/1.0/2.0mg) | Wegovy pen (0.25/0.5/1.0/1.7/2.4mg) |
Administer the missed dose as soon as you remember. Then resume your regular weekly injection schedule. The next dose should be at least 2 days (48 hours) after the make-up dose.
Skip the missed dose entirely. Resume your regular weekly injection on the next scheduled day. Do not double-dose to compensate. The ~7-day half-life means a single missed dose has minimal clinical impact.
Extended interruption: If semaglutide is stopped for more than 2 weeks and then restarted, clinical guidelines recommend restarting at 0.25 mg and re-titrating. Jumping back to a higher dose after a prolonged break significantly increases GI side effect risk.
GI side effects are dose-dependent and most pronounced during the first 4–8 weeks at each new dose level. They typically diminish with continued use.
Semaglutide has more human clinical trial data than any other compound on this site. The five most relevant trials for dosing context:
14.9% mean weight loss vs 2.4% placebo. 69.1% of participants lost ≥5% body weight.
9.6% weight loss in T2D population vs 3.4% placebo. Lower than non-diabetic population.
16.0% weight loss with intensive behavioral therapy vs 5.7% placebo + therapy.
20% reduction in MACE (major adverse cardiovascular events). First cardiovascular outcome trial for a GLP-1 in non-diabetic obesity.
26% reduction in MACE in T2D population. Established cardiovascular benefit for Ozempic.
Tirzepatide (GLP-1 + GIP dual agonist) produced 22.5% mean weight loss at 15 mg/week in SURMOUNT-1. Retatrutide (GLP-1 + GIP + glucagon triple agonist) produced 24.2% weight loss at 12 mg/week in Phase 2 TRIUMPH data. Neither has been compared head-to-head with semaglutide in a randomized trial.
The standard starting dose for both Ozempic (T2D) and Wegovy (obesity) is 0.25 mg once weekly for the first 4 weeks. This initiation dose is below the therapeutic threshold — its purpose is to establish gastrointestinal tolerance before escalating. Do not increase the dose before 4 weeks regardless of tolerability.
For Wegovy (obesity indication), the maximum approved dose is 2.4 mg once weekly, reached after a 16–20 week titration. For Ozempic (T2D indication), the maximum approved dose is 2.0 mg once weekly. The 2.4 mg dose is only available in the Wegovy pen — Ozempic pens do not deliver this dose.
Appetite suppression typically begins within the first 1–2 weeks at the 0.5 mg dose. Measurable weight loss (≥5%) is typically seen by weeks 8–12. Maximum weight loss efficacy is reached at the 2.4 mg maintenance dose after 16–20 weeks of titration. The STEP 1 trial showed continued weight loss through 68 weeks.
If you miss a dose and it has been 5 days or fewer since the scheduled injection, administer the missed dose as soon as possible and resume your regular weekly schedule. If more than 5 days have passed, skip the missed dose and resume your regular schedule on the next scheduled day. Do not double-dose. The once-weekly half-life (~7 days) means a single missed dose has minimal clinical impact.
The titration schedule is designed to minimize gastrointestinal side effects. Accelerating the titration increases the risk of nausea, vomiting, and treatment discontinuation. Clinical trials used the standard 4-week intervals between dose escalations. Some prescribers may adjust the schedule based on individual tolerability, but faster titration is generally not recommended.
Yes. For T2D (Ozempic), the maintenance dose is typically 0.5–1.0 mg/week, with a maximum of 2.0 mg/week. For obesity (Wegovy), the target maintenance dose is 2.4 mg/week after a 16–20 week titration. The higher dose used in obesity treatment produces greater weight loss but also higher rates of gastrointestinal side effects.
In the STEP clinical trials, the 2.4 mg/week dose produced a mean weight loss of 14.9% at 68 weeks (STEP 1). This is the dose used in the Wegovy approval. For research purposes, the titration schedule is: 0.25 mg (weeks 1–4) → 0.5 mg (weeks 5–8) → 1.0 mg (weeks 9–12) → 1.7 mg (weeks 13–16) → 2.4 mg (week 17+).
Tirzepatide (Mounjaro/Zepbound) is dosed at 2.5 mg/week initially, titrating to 5–15 mg/week. At its maximum dose of 15 mg/week, tirzepatide produced 22.5% mean weight loss in the SURMOUNT-1 trial vs 14.9% for semaglutide 2.4 mg in STEP 1. The two drugs have not been compared head-to-head in a randomized trial.
Medical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.